Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Siegel DS et al. Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1.
Daratumumab granted breakthrough drug status.
Laubach JP et al. Expert Opin Investig Drugs. 2014 Feb 20. [Epub ahead of print].
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
Hassan SB et al. Immunopharmacol Immunotoxicol. 2014 Feb 21. [Epub ahead of print].
The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P. Expert Rev Hematol. 2014 Feb 12. [Epub ahead of print].
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells.
Rapoport AP et al. Clin Cancer Res. 2014 Feb 11. [Epub ahead of print].
The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma.
Rasche L et al. Ann Hematol. 2014 Feb 14. [Epub ahead of print].